US Patent Issued to The Regents of the University of California on Dec. 2 for "Chemically controlled monoclonal antibody target engagement" (California Inventors)

ALEXANDRIA, Va., Dec. 2 -- United States Patent no. 12,486,334, issued on Dec. 2, was assigned to The Regents of the University of California (Oakland, Calif.).

"Chemically controlled monoclonal antibody target engagement" was invented by Charles S. Craik (San Francisco), Kevan M. Shokat (San Francisco), Ziyang Zhang (San Francisco) and Peter J. Rohweder (San Francisco).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure relates generally to antibodies reactive with tumor-specific neoantigens, as well as neoantigen-binding fragments thereof. The present disclosure also relates to nucleic acids, expression cassettes, and expression vectors encoding the antibodies and neoantigen-binding fragme...